SemBioSys submits IND for safflower-produced insulin
This article was originally published in Scrip
Executive Summary
SemBioSys Genetics has submitted an IND application to the US FDA for a safflower-produced recombinant human insulin, with a view to starting a Phase I/II trial in the fourth quarter.